Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
2018年8月30日 更新者:GlaxoSmithKline
Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Hip Fracture Surgery
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
研究概览
研究类型
介入性
注册 (实际的)
48
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
- GSK Investigational Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
20年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Patients undergoing hip fracture surgery within 10 days following the time of fracture of the hip (proximal femur) (or following the time of fracture estimated from trauma).
Exclusion Criteria:
- Active, clinically significant bleeding (excluding drainage).
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of Major Bleeding During Treatment Period
大体时间:From the first study drug injection up to Day 17
|
Rate (%) was defined as number of events divided by the number of participants evaluated multiplied by 100.
Signs and symptoms suggestive of venous thromboembolic events (VTE) included, but were not limited to lower extremity deep vein thrombosis (DVT): erythema, warmth, pain, swelling, tenderness and pulmonary embolism (PE): pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia.
Intended treatment period started 24±2 hours after surgical closure.
Venogram was obtained not later than 2 calendar days after the last study drug administration (between Day 11 and 17).
These events were adjudicated by the Central Independent Adjudication Committee of Efficacy (CIACE).
|
From the first study drug injection up to Day 17
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of PE During Treatment Period
大体时间:Up to Day 17
|
Rate (%) was defined as number of events divided by the number of participants evaluated multiplied by 100.
Signs and symptoms suggestive of VTE included, but were not limited to lower extremity PE: pleuritic chest pain, dyspnea, cough, hemoptysis, syncope, light-headedness/dizziness, tachypnea, and tachycardia.
Intended treatment period started 24±2 hours after surgical closure.
Venogram was obtained not later than 2 calendar days after the last study drug administration (between Day 11 and 17).
These events were adjudicated by the CIACE.
It was evaluated from the first study drug injection up to Day 17 or to first venogram, whichever occurred first.
|
Up to Day 17
|
|
Rate of DVT During Treatment Period
大体时间:Up to Day 17
|
Rate (%) was defined as number of events divided by the number of patients evaluated multiplied by 100.
Signs and symptoms suggestive of VTE included, but were not limited to lower extremity DVT: erythema, warmth, pain, swelling, tenderness.
Intended treatment period started 24±2 hours after surgical closure.
Venogram was obtained not later than 2 calendar days after the last study drug administration (between Day 11 and 17).
These events were adjudicated by the CIACE.
It was evaluated from the first study drug injection up to Day 17 or to first venogram, whichever occurred first.
|
Up to Day 17
|
|
Rate of Proximal DVT During Treatment Period
大体时间:Up to Day 17
|
Rate (%) was defined as number of events divided by the number of participants evaluated multiplied by 100.
Signs and symptoms suggestive of VTE included, but were not limited to lower extremity DVT: erythema, warmth, pain, swelling, tenderness.
Intended treatment period started 24±2 hours after surgical closure.
Venogram was obtained not later than 2 calendar days after the last study drug administration (between Day 11 and 17).
These events were adjudicated by the CIACE.
It was evaluated from the first study drug injection up to Day 17 or to first venogram, whichever occurred first.
|
Up to Day 17
|
|
Rate of Distal Only DVT During Treatment Period
大体时间:Up to Day 17
|
Rate (%) was defined as number of events divided by the number of participants evaluated multiplied by 100.
Signs and symptoms suggestive of VTE included, but were not limited to lower extremity DVT: erythema, warmth, pain, swelling, tenderness.
Intended treatment period started 24±2 hours after surgical closure.
Venogram was obtained not later than 2 calendar days after the last study drug administration (between Day 11 and 17).
These events were adjudicated by the CIACE.
It was evaluated from the first study drug injection up to Day 17 or to first venogram, whichever occurred first.
|
Up to Day 17
|
|
Number of Participants With Major Bleeding During Treatment Period
大体时间:From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
Major bleeding events were defined as clinically unusual bleeding meeting any of the following criteria: fatal bleeding, bleeding including retroperitoneal and intracranial bleeding or bleeding into a critical organ (eye, adrenal gland, pericardium, spine), reoperation due to bleeding/hematoma at the operative site, bleeding leading to a hemoglobin (Hb) fall >=2 grams per deciliter (g/dL, 1.6 millimoles per liter [mmol/L]) within 48 hour of the bleed, bleeding that required a transfusion of red blood cell or whole blood derived from >=900 millilters (mL) of whole blood within 48 hours of the bleed (excluding the autologous transfusion except for the treatment of bleeding adverse event (AE) and bleeding leading to the bleeding index (BI) >=2.
Major bleeding events were adjudicated by the Central Independent Adjudication Committee of Safety (CIACS).
|
From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
|
Number of Participants With Minor Bleeding and Any Bleeding (Major and/or Minor Bleeding)
大体时间:From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
Minor bleeding and any bleeding (major and/or minor bleeding) events were adjudicated by the CIACS.
Minor bleeding was defined as clinically overt bleeding not meeting the criteria for major bleeding and considered more than expected in the clinical context.
Any bleeding (major and/or minor bleeding) could be recorded may be major and/or minor.
|
From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
|
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death
大体时间:From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use.
The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.
|
From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
|
Number of Transfused Participants
大体时间:From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
Blood product transfusions consisted of packed red blood cells or fresh frozen plasma or both.
This was done between Day 2 and 2 calendar days after the last injection.
|
From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
|
Summary of Units Transfused
大体时间:From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
Blood product transfusions consisted of packed red blood cells or fresh frozen plasma or both.
This was done between Day 2 and 2 calendar days after the last injection.
|
From the first study drug injection up to 2 days after the last study drug injection (approximately up to Day 17)
|
|
Rate of Symptomatic DVT
大体时间:Up to Day 17
|
Rate (%) was defined as number of events divided by the number of participants evaluated multiplied by 100.
Signs and symptoms suggestive of VTE included, but were not limited to lower extremity DVT: erythema, warmth, pain, swelling, tenderness.
Intended treatment period started 24±2 hours after surgical closure.
Venogram was obtained not later than 2 calendar days after the last study drug administration (between Day 11 and 17).
These events were adjudicated by the CIACE.
It was evaluated from the first study drug injection up to Day 17 or to first venogram, whichever occurred first.
|
Up to Day 17
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2006年2月16日
初级完成 (实际的)
2006年10月26日
研究完成 (实际的)
2006年10月26日
研究注册日期
首次提交
2006年5月1日
首先提交符合 QC 标准的
2006年5月1日
首次发布 (估计)
2006年5月3日
研究记录更新
最后更新发布 (实际的)
2018年9月4日
上次提交的符合 QC 标准的更新
2018年8月30日
最后验证
2018年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.